Metastatic and synchronous ovarian involvement in low-risk endometrial cancer; clinicopathological analysis with detection of DNA mismatch repair deficiency


Creative Commons License

Gezer Ş., Yaprak Bayrak B.

GINEKOLOGIA POLSKA, cilt.92, sa.9, ss.599-606, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 92 Sayı: 9
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5603/gp.a2021.0150
  • Dergi Adı: GINEKOLOGIA POLSKA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, Gender Studies Database, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.599-606
  • Anahtar Kelimeler: low-risk endometrial cancer, ovarian involvement, ovarian metastasis, synchronous ovarian cancer, YOUNG-WOMEN, IMMUNOHISTOCHEMISTRY, ADENOCARCINOMA, MALIGNANCY, SURVIVAL
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Objectives: This study aimed to investigate ovarian involvement in low-risk endometrial cancer, the associated risk factors,
and impact on overall survival. We attempted to explore the differences in mismatch repair (MMR) deficiency between
metastatic and synchronous ovarian tumoral involvement.
Material and methods: This was a retrospective study of patients with low-risk endometrial cancer who were treated at
a tertiary center between January 2006 and December 2019. The primary outcome measures were the incidence and risk
factors associated with metastatic and synchronous tumoral involvement of the ovary. Overall, survival data were also
analyzed. Metastatic and synchronous tumors were compared with each other in terms of MMR deficiency with IHC staining.
Results: From a total of 360 low-risk endometrial cancer patients, 10 (2.8%) had ovarian metastasis and 12 (3.3%) had
synchronous ovarian involvement. The median age of patients with metastasis was significantly lower than that of patients
without ovarian involvement (49 vs 57 years, p = 0.004). Most patients in the metastatic group were in the < 50 age group
(p < 0.001) and premenopausal period (p = 0.001). As a result of IHC staining performed on patients with ovarian involvement,
MMR deficiency was found in six (60%) patients in the metastatic group and six (50%) patients in the synchronous
group. No significant difference was found in overall survival between groups.
Conclusions: Younger age and premenopausal status were risk factors associated with ovarian metastasis. Overall survival
did not show differences between all groups, and MMR deficiency was similar between metastatic and synchronous groups.